Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 1.00 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21504226 | 1.00 | IDO1 (1.00) | IDO1FPR2GRM5NPC1RAB9A | |
| SCHEMBL30056253 | 1.00 | IDO1 (1.00) | IDO1FPR2GRM5NPC1RAB9A | |
| SCHEMBL21496407 | 0.93 | IDO1 (1.00) | IDO1 | |
| SCHEMBL21496489 | 0.88 | IDO1 (1.00) | IDO1 | |
| SCHEMBL30056074 | 0.88 | IDO1 (0.80) | IDO1FPR2GRM5SMN1; SMN2 | |
| SCHEMBL24118599 | 0.88 | IDO1 (1.00) | IDO1 | |
| SCHEMBL21496359 | 0.88 | IDO1 (0.80) | IDO1FPR2GRM5SMN1; SMN2 | |
| SCHEMBL30055973 | 0.88 | IDO1 (1.00) | IDO1 | |
| SCHEMBL24117923 | 0.88 | IDO1 (0.78) | IDO1GRM5 | |
| SCHEMBL24117918 | 0.81 | IDO1 (0.69) | IDO1FPR2GRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885FPR2 1585/4885GRM5 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.